4.35
-0.48(-9.94%)
Currency In USD
| Previous Close | 4.83 |
| Open | 5.71 |
| Day High | 5.71 |
| Day Low | 4.31 |
| 52-Week High | 414.7 |
| 52-Week Low | 4.03 |
| Volume | 422,020 |
| Average Volume | 1.63M |
| Market Cap | 3.21M |
| PE | 0.02 |
| EPS | 264.12 |
| Moving Average 50 Days | 8.97 |
| Moving Average 200 Days | 95.46 |
| Change | -0.48 |
If you invested $1000 in ReShape Lifesciences Inc. (RSLS) since IPO date, it would be worth $0 as of June 05, 2025 at a share price of $4.35. Whereas If you bought $1000 worth of ReShape Lifesciences Inc. (RSLS) shares 5 years ago, it would be worth $0.02 as of June 05, 2025 at a share price of $4.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
GlobeNewswire Inc.
Jun 03, 2025 12:31 PM GMT
IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial por
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
GlobeNewswire Inc.
May 07, 2025 12:31 PM GMT
Effective as of Commencement of Trading on May 9, 2025IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its
ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
GlobeNewswire Inc.
May 02, 2025 12:31 PM GMT
Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques IRVI